http://www.fresenius.com en-us Tue, 31 Mar 2020 00:00:00 +0200 Tue, 31 Mar 2020 00:00:00 +0200 Tue, 31 Mar 2020 08:00:00 +0100 <![CDATA[Fresenius successfully places bonds with a volume of 750 million euros]]> Fresenius today successfully places bonds with a volume of €750 million.

]]>
Mon, 30 Mar 2020 08:00:00 +0100 <![CDATA[Fresenius postpones 2020 Annual General Meeting]]> New date will be specified and communicated as soon as reliable planning is possible - Health and safety of shareholders and employees is our priority

]]>
Fri, 27 Mar 2020 08:00:00 +0100 <![CDATA[Fresenius takes comprehensive measures to combat COVID 19 pandemic in Germany]]> Helios Germany is increasing number of intensive care beds by two thirds. Law to ease financial burden on hospitals likely to offset large part of sales losses and cost increases. Digital healthcare offerings facilitate continuous medical care for chronically ill and rehabilitation patients.

]]>
Tue, 24 Mar 2020 08:00:00 +0100 <![CDATA[Fresenius Kabi resumes normal operations in China]]> With virtually all of Fresenius Kabi’s manufacturing staff in China returning to work post government-imposed COVID-19 quarantine restrictions, the company is ramping-up production back to normal levels. With a further stabilization of the situation, Fresenius Kabi also expects a gradual resumption of its sales force activities in China. Even though Fresenius Kabi faced challenges due to the COVID-19 pandemic and the quarantine measures, there was no major interruption of production. Thus, the company can supply the Chinese population with essential pharmaceuticals and medical devices.

]]>
Fri, 20 Mar 2020 08:00:00 +0100 <![CDATA[Fresenius Helios makes significant contribution to combating COVID-19 crisis in Spain]]> All Quirónsalud hospitals are fully operational and managed by Quirónsalud in close coordination with the health authorities. Rumors about a “nationalization” are without any basis.

]]>
Wed, 18 Mar 2020 08:00:00 +0100 <![CDATA[Fresenius annual report 2019 online available]]> Our Annual Report 2019 is now available as a full-content PDF download and as an online short-version with the highlights. Annual Report (PDF)  Online short-version

]]>
Wed, 18 Mar 2020 08:00:00 +0100 <![CDATA[Fresenius subsidiary Curalie acquires Digitale Gesundheitsgruppe]]> Curalie, a subsidiary of Fresenius, has acquired Digitale Gesundheitsgruppe (DGG), one of its main competitors in Germany. Curalie and DGG both develop digital healthcare offerings to help patients with chronic illnesses. DGG targets family and specialist physicians with its “TeLiPro” telemedicine platform, while Curalie develops digital solutions for rehabilitation and aftercare. Combining the two companies creates the first provider that in all sectors of healthcare can digitally support patients during outpatient and inpatient care and through to aftercare.

]]>
Mon, 16 Mar 2020 08:00:00 +0100 <![CDATA[Fresenius Kabi launches IV solution in the U.S.]]> Sodium Chloride 3% is the newest addition to the company’s IV solution portfolio.

]]>
Thu, 20 Feb 2020 08:00:00 +0100 <![CDATA[Fresenius Kabi and Vifor Pharma create joint venture in China for i.v. iron portfolio ]]> Fresenius Kabi and Vifor Pharma have formed a joint venture in China to provide patients access to vital blood management treatment. It will combine Vifor Pharma’s leading intravenous drug portfolio for the treatment of iron deficiency with Fresenius Kabi’s strong and long-year presence in the market to benefit both patients and the healthcare system in China. The joint venture will focus on marketing, market access and medical affairs activities whereas Fresenius Kabi will be fully responsible for the commercialization of the intravenous iron portfolio. The joint company will be 55% owned by Vifor Pharma and 45% by Fresenius Kabi. Financial terms were not disclosed.

]]>
Thu, 20 Feb 2020 08:00:00 +0100 <![CDATA[Fresenius reports 16th consecutive record year - Significant investments into growth – Healthy growth for 2020 expected – Medium-term growth targets confirmed]]> - Good organic sales growth across all business segments
- Fresenius Kabi’s excellent Emerging Markets growth partially offsets softer development in North America
- Fresenius Helios shows continued stabilization in Germany and strong growth in Spain
- Fresenius Medical Care expects to show strong growth in 2020
- 27th consecutive dividend increase proposed

]]>
Wed, 19 Feb 2020 08:00:00 +0100 <![CDATA[Fresenius Helios acquires first hospital in Bogotá, continuing expansion in Colombia’s private hospital market]]> Quirónsalud, the largest private hospital group in Spain and part of Fresenius Helios, has signed an agreement to acquire Clínica de la Mujer in Bogotá, further expanding the company’s presence in Colombia’s attractive private hospital market.

]]>
Wed, 05 Feb 2020 08:00:00 +0100 <![CDATA[Fresenius Kabi diversifies U.S. product portfolio]]> With the launch of a Glucagon Emergency Kit, Fresenius Kabi offers an FDA-approved and cost-effective alternative to treat severe hypoglycemic episodes in people with diabetes. This is the company’s first pharma product sold and used primarily outside hospitals in the U.S.

]]>
Tue, 21 Jan 2020 08:00:00 +0100 <![CDATA[Fresenius Kabi enters into joint venture to advance new cell and gene therapies]]> Fresenius Kabi, Bio-Techne and Wilson Wolf have formed a new joint venture to support researchers and biopharmaceutical companies in the field of cell and gene therapy. The joint venture is owned equally by the three partners and will focus on providing scalable manufacturing technologies and processes needed to develop and commercialize new cell and gene therapies. No other financial terms were disclosed.

]]>
Thu, 16 Jan 2020 08:00:00 +0100 <![CDATA[Fresenius Helios trains doctors in antibiotics management]]> Fresenius Helios has started training experts in antibiotics management to combat the growing threat from multi-resistant bacteria. In the coming years, more than 600 doctors will be trained at the company’s 86 hospitals in Germany on the correct way to handle antibiotics. These doctors will raise awareness of the problem among colleagues and be available for consultations with them. In addition, Fresenius Helios is introducing a system under which each hospital will report on its antibiotics usage.

]]>
Tue, 07 Jan 2020 08:00:00 +0100 <![CDATA[Fresenius successfully places bonds with a volume of 750 million euros]]> Fresenius today successfully placed bonds with a volume of €750 million.

]]>
Mon, 23 Dec 2019 08:00:00 +0100 <![CDATA[Fresenius Helios acquires leading private hospital in Colombia]]> Quirónsalud, the largest private hospital group in Spain and part of Fresenius Helios, has signed an agreement to acquire Centro Médico Imbanaco (CMI) in Cali, further expanding the company’s presence in Colombia’s attractive private hospital market.

]]>
Fri, 20 Dec 2019 08:00:00 +0100 <![CDATA[Fresenius Kabi launches IV Drug in the U.S.]]> Busulfan, a drug for certain blood cancers, expands the company’s broad oncology portfolio.

]]>
Thu, 19 Dec 2019 08:00:00 +0100 <![CDATA[Fresenius Kabi launches IV Drug in the U.S.]]> Dicyclomine Hydrochloride Injection, an antispasmodic agent, expands Fresenius Kabi’s large and growing generic critical care portfolio.  

]]>
Wed, 11 Dec 2019 08:00:00 +0100 <![CDATA[Fresenius Kabi launches IV Drug in the U.S.]]> Ertapenem, an antibiotic, expands Fresenius Kabi's anti-infective portfolio.

]]>
Tue, 10 Dec 2019 08:00:00 +0100 <![CDATA[Fresenius Helios awards new innovation prize]]> Fresenius Helios has awarded its inaugural Helios-Pro-Inno Prize for outstanding innovation and projects in patient care and hospital management. Three different projects at Helios Wuppertal, Helios Berlin-Buch and Helios Bad Saarow hospitals in Germany were honored: A color and lighting concept that demonstrably improved the well-being of intensive care patients and even reduced their need for certain medications; the appointment of a “Feel Good Manager” for resolving employees’ problems in the workplace, and an antibiotics reporting system developed in response to the growing threat from multi-resistant bacteria. A jury of eight members, from different occupational groups, chose the Helios-Pro-Inno Prize winners from more than 70 entries.

]]>